IntelGenx Technologies Corp. Form 8-K May 21, 2014

Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

May 21, 2014

Date of Report (Date of Earliest Event Reported)

IntelGenx Technologies Corp.

(Exact Name of Registrant as Specified in its Charter)

870638336

<u>000-31187</u>

(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)	
6425 Abrams, Ville St- Laurent, (Address of principal executi	Quebec, Canada	<u>H4S 1X9</u> (Zip Code)	
Check the appropriate box below if the registrant under any of the following	2	o simultaneously satisfy the filing obligation	n of
	ile 14a-12 under the Exchange A ons pursuant to Rule 14d-2(b) ur		

Edgar Filing: IntelGenx Technologies Corp. - Form 8-K

Item 8.01 Other Events - News Release

IntelGenx and RedHill Biopharma Report Positive Bioavailability Study Results in Support of Planned European Marketing Application in Q3/2014 for Anti-Migraine VersaFilm Product

Exhibit Description
99.1 Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTELGENX TECHNOLOGIES CORP.

Dated: May 21, 2014 By: /s/ Rajiv Khosla

Rajiv Khosla

President and Chief Executive Officer